SCHEMBL5687339

SCHEMBL5687339

O=C(O)Cc1ccc(OC2CCN(C(=O)Oc3ccc(Oc4ccc(Cl)cn4)cc3)CC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
LIPE Q05469 12/20 0.49
EPHX2 P34913 1/20 0.45
BCHE P06276 1/20 0.44
EGLN1 Q9GZT9 1/20 0.43
GPR119 Q8TDV5 1/20 0.42
CNR1 P21554 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
HRH1 P35367 1/20 0.41
CCR3 P51677 1/20 0.41
KCNH2 Q12809 1/20 0.41
ACACB O00763 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5687732 0.88 LIPE (0.53) LIPEBCHEEGLN1NPC1RAB9A
SCHEMBL5689876 0.87 LIPE (0.51) LIPEEPHX2BCHEGPR119NPC1
SCHEMBL5687237 0.86 LIPE (0.68) LIPEBCHE
SCHEMBL5688397 0.86 LIPE (0.43) LIPEBCHEEGLN1GPR119ACACB
SCHEMBL5687680 0.85 LIPE (0.52) LIPEBCHEGPR119NPC1RAB9A
SCHEMBL5688203 0.85 LIPE (0.50) LIPEEPHX2BCHEGPR119NPC1
SCHEMBL5687837 0.82 EPHX2 (0.47) EPHX2CNR1HRH1CCR3KCNH2
SCHEMBL5715011 0.81 SCN9A (0.47) LIPEBCHEEGLN1HRH3
SCHEMBL5688288 0.80 EPHX2 (0.51) EPHX2NPC1RAB9AHRH1CCR3
SCHEMBL5650051 0.80 LIPE (0.72) LIPEBCHENPC1RAB9AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160851-A1 Substituted piperidine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636207-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111032-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160851-A1 Substituted piperidine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636207-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111032-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160851-A1 Substituted piperidine carbamates LIPE, PNLIP, LIPC LIPE 1/4885EPHX2 3290/4885BCHE 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.